APP and Alzheimer disease: Reducing GSAP levels diminishes the partitioning of APP-CTF into lipid rafts, specifically at the mitochondria-associated membrane (MAM), and also decreases γ-secretase activity involved in Aβ production, and decreasing GSAP expression mitigates pathological effects linked to AD (Xu et al., 2021).